RxDoctor Payments DataLook up a doctor →

Jeremy Deutsch, MD

Hematology & Oncology · Wichita, KSNPI 1528263043

Payments from drug & device makers

$27,998in general payments, 2019–2025

Across 1,043 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Daiichi Sankyo Inc.$2K
  • Seagen Inc.$2K
  • AbbVie$2K
  • Novartis$1K
  • Pfizer$1K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)53$3,880
Daiichi Sankyo Inc.21$2,118
Seagen Inc.29$1,952
AbbVie43$1,543
Novartis89$1,334
Pfizer78$1,025
Dova Pharmaceuticals3$1,007
Karyopharm Therapeutics Inc.14$977
Rigel Pharmaceuticals, Inc.9$955
Bristol Myers Squibb54$954
E.r. Squibb & Sons, L.L.C.77$940
Verastem, Inc.4$916
Johnson & Johnson(2 entities)38$773
Astellas Pharma US Inc29$550
Genentech USA, Inc.27$524
Gilead(2 entities)36$523
Verity Pharmaceuticals Inc.1$500
Amgen34$468
Merck31$463
Sanofi27$441
EMD Serono, Inc.30$412
Takeda Pharmaceuticals U.S.A., Inc.14$368
Eisai Inc.12$314
Exelixis Inc.16$311
GSK22$286
Regeneron Healthcare Solutions, Inc.13$275
Array Biopharma Inc22$244
Bayer13$231
Jazz Pharmaceuticals Inc.10$207
AVEO Pharmaceuticals, Inc.11$196
Tersera Therapeutics LLC8$180
Servier Pharmaceuticals LLC11$176
Lilly USA, LLC10$170
Epizyme, Inc.8$142
Sobi, Inc4$130
Sun Pharmaceutical Industries Inc.8$129
Incyte Corporation8$125
Boehringer Ingelheim6$112
Pharmacyclics LLC, An Abbvie Company6$107
Beigene USA, Inc.8$104
Comsort, Inc1$100
Ipsen Biopharmaceuticals, Inc5$91
Pharmaessentia USA Corporation5$85
Genmab U.S., Inc.5$82
CTI Biopharma Corp.5$79
Apellis Pharmaceuticals, Inc.3$71
US Oncology Corporate, Inc.1$70
Mirati Therapeutics, Inc.4$68
Springworks Therapeutics, Inc.4$67
Spectrum Pharmaceuticals Inc.4$64
Taiho Oncology, Inc.4$63
Pharmacosmos Therapeutics Inc.3$60
Blueprint Medicines Corporation3$57
Legend Biotech USA Inc.3$56
Heron Therapeutics, Inc.4$54
Recordati_rare_diseases_inc.3$53
Stemline Therapeutics Inc.3$49
Foundation Medicine, Inc.2$48
Dendreon Pharmaceuticals LLC2$45
Octapharma USA, Inc.2$42

How this compares

$27,998 in reported general payments places this provider in the 60th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024
$11,377,402
Medicare patients
1,821
Services billed
452,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Wichita

See the full list for Kansas →

Where these figures come from

Is this you, or does something look wrong? →